Progression to the persistent form in asymptomatic paroxysmal atrial fibrillation

Circulation Journal

Volumn 78, Issue 5, 2014, Pages 1121-1126

  Senoo, Keitaro ^a   Suzuki, Shinya ^a   Otsuka, Takayuki ^a   Sagara, Koichi ^a   Matsuno, Shunsuke ^a   Kano, Hiroto ^a   Uejima, Tokuhisa ^a   Oikawa, Yuji ^a   Yajima, Junji ^a   Nagashima, Kazuyuki ^a   Kirigaya, Hajime ^a   Sawada, Hitoshi ^a   Aizawa, Tadanori ^a   Yamashita, Takeshi ^a  

^a THE CARDIOVASCULAR INSTITUTE   (Japan)

Author keywords

Asymptomatic atrial fibrillation; Atrial fibrillation; Epidemiology; Progression

Indexed keywords

ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DABIGATRAN; DIGITALIS; DIURETIC AGENT; WARFARIN;

ARTICLE; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; COHORT ANALYSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DYSLIPIDEMIA; ECHOCARDIOGRAPHY; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; INFORMATION PROCESSING; MEDICAL RECORD REVIEW; MORBIDITY; PULMONARY VEIN ISOLATION; QUANTITATIVE ANALYSIS; RISK FACTOR; SEX DIFFERENCE; TREATMENT OUTCOME;

EID: 84899652012     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-13-1272     Document Type: Article

References (19)

1. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370-2375.
2. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: The Framingham study. N Engl J Med 1982; 306: 1018-1022.
3. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the management of patients with atrial fibrillation). J Am Coll Cardiol 2006; 48: 854-906.
4. Kato T, Yamashita T, Sagara K, Fu LT. Progressive nature of paroxysmal atrial fibrillation. Circ J 2004; 68: 568-572.
5. Kerr CR, Humphries KH, Talajic M, Klein GJ, Connolly SJ, Green M, et al. Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: Results from the Canadian Registry of Atrial Fibrillation. Am Heart J 2005; 149: 489-496.
6. De Vos CB, Pisters R, Nieuwlaat R, Prins MH, Tieleman RG, Coelen RJ, et al. Progression from paroxysmal to persistent atrial fibrillation. J Am Coll Cardiol 2010; 55: 725-731.
7. Flaker GC, Belew K, Beckman K, Vidaillet H, Kron J, Safford R, et al. Asymptomatic atrial fibrillation: Demographic features and prognostic information from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J 2005; 149: 657-663.
8. Senoo K, Suzuki S, Sagara K, Otsuka T, Matsuno S, Funada R, et al. Distribution of first-detected atrial fibrillation patients without structural heart diseases in symptom classifications. Circ J 2012; 76: 1020-1023.
9. Potpara TS, Polovina MM, Marinkovic JM, Lip GY. A comparison of clinical characteristics and long-term prognosis in asymptomatic and symptomatic patients with first-diagnosed atrial fibrillation: The Belgrade Atrial Fibrillation Study. Int J Cardiol 2013; 168: 4744-4749.
10. Suzuki S, Yamashita T, Otsuka T, Sagara K, Uejima T, Oikawa Y, et al. Prevalence and prognosis of patients with atrial fibrillation in Japan: A prospective cohort of Shinken Database 2004. Circ J 2008; 72: 914-920.
11. Suzuki S, Yamashita T, Otsuka T, Sagara K, Uejima T, Oikawa Y, et al. Recent mortality of Japanese patients with atrial fibrillation in an urban city of Tokyo. J Cardiol 2011; 58: 116-123.
12. Suzuki S, Yamashita T, Ohtsuka T, Sagara K, Uejima T, Oikawa Y, et al. Body size and atrial fibrillation in Japanese outpatients. Circ J 2010; 74: 66-70.
13. Suzuki S, Otsuka T, Sagara K, Matsuno S, Funada R, Uejima T, et al. Dabigatran in clinical practice for atrial fibrillation with special reference to activated partial thromboplastin time. Circ J 2012; 76: 755-757.
14. Suzuki S, Sagara K, Otsuka T, Matsuno S, Funada R, Uejima T, et al. Gender-specific relationship between serum uric acid level and atrial fibrillation prevalence. Circ J 2012; 76: 607-611.
15. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-2870.
16. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on Atrial Fibrillation. Chest 2010; 137: 263-272.
17. Flaker GC, Belew K, Beckman K, Vidaillet H, Kron J, Safford R, et al. Asymptomatic atrial fibrillation: Demographic features and prognostic information from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J 2005; 149: 657-663.
18. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, et al. Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-1833.
19. Eckstein J, Verheule S, de Groot NM, Allessie M, Schotten U. Mechanisms of perpetuation of atrial fibrillation in chronically dilated atria. Prog Biophys Mol Biol 2008; 97: 435-451.